Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8Other hematologic neoplasm 3Thoracic 2Plasma cell 2Dermatologic 2Classical hematology 2Tumor-Agnostic 1Lymphoid 1Genitourinary 1Endocrine 1CNS 1Breast 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Specimen Handling 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anti-Bacterial Agents × Dermatologic × Clear all
NCT06207786 2024-11-25

Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery

Mayo Clinic

Phase NA Withdrawn
Dermatologic

Skin Neoplasms

NCT03817125 2024-06-06

MCGRAW

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
14 enrolled 22 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡